HC Wainwright & Co. reiterates Buy rating on Zenas BioPharma, $44 price target

HC Wainwright & Co. reiterated their Buy rating on Zenas BioPharma's stock with a price target of $44.00.The price target implies an upside of 64.4% from the Sep 29 close of $26.76.Key takeaways from the analyst notePromising Pipeline Developments: Zenas BioPharma has upcoming clinical milestones…